1:00 30/09/2014 Pfizer Inc.: Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology ...
Pfizer Inc.: Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology ...
The Wall Street Transcript - Sep 30, 2014
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Kyowa Hakko Kirin (Tokyo:4151), announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's PF-05082566, ...

17:52 29/09/2014 Pfizer Inc. Stock Fails To Break Out: Is It Headed Back Down?
Pfizer Inc. Stock Fails To Break Out: Is It Headed Back Down?
Benzinga - Sep 29, 2014
Pfizer Inc. (NYSE: PFE) shareholders have experienced the short-term euphoria of seeing their stock rally a massive 10 percent from August to September.

16:00 29/09/2014 Can Pfizer Grow Without A Big Acquisition?
Can Pfizer Grow Without A Big Acquisition?
Seeking Alpha (registration) - Sep 29, 2014
While Pfizer may shift its sights to another big acquisition, valuations may be stretched and smaller portfolio acquisitions may be more attractive.
Pfizer Inc. (NYSE:PFE) Acquires InnoPharma, Inc. For $225 million Upfront ... - USMarketsDaily
Pfizer Inc.'s (NYSE:PFE) New Acquisition Will Strengthen Injectable's Segment ... - eMarketsDaily

13:52 29/09/2014 Better Dividend Stock: Johnson & Johnson or Pfizer, Inc?
Better Dividend Stock: Johnson & Johnson or Pfizer, Inc?
Motley Fool - Sep 29, 2014
According to Susanna Kim of ABC News, dividend yield and dividend growth comprised 90% of the total nominal returns for investors in the S&P 500 between 1910 and 2010.

13:45 29/09/2014 Pfizer Announces Positive Data For Cancer Drug Xalkori
Pfizer Announces Positive Data For Cancer Drug Xalkori
Bidness ETC - Sep 29, 2014
Pfizer Inc. (PFE) announced extended Phase I trial results for Xalkori (crizotinib) at the European Society for Medical Oncology (ESMO) meeting on Saturday.
Pfizer's Lung Cancer Drug Helps Patients With Gene Defect - Bloomberg
Pfizer's Drug Shows Promising Results in Rare Lung Cancer Patients - Beta Wired

11:41 27/09/2014 Pfizer drug effective in patients with rare lung cancer, study shows
Pfizer drug effective in patients with rare lung cancer, study shows
Fox News - Sep 27, 2014
Pfizer Inc's Xalkori, which treats lung cancer patients with a specific gene mutation, proved effective in shrinking tumors in those with an even rarer form of the disease, according to data presented at a medical meeting on Saturday.

21:15 26/09/2014 GlycoMimetics In The Red After Pfizer Delays Trial
GlycoMimetics In The Red After Pfizer Delays Trial
Bidness ETC - Sep 26, 2014
GlycoMimetics, Inc. (GLYC) stock closed down more than 14% on the Nasdaq today, after the company said its licensing partner, Pfizer Inc. (PFE), has delayed initiating a phase 3 trial of Rivipansel (GM-1071). Rivipansel, the most advanced pipeline ...
Pharma Stock Updates - GlycoMimetics Inc (NASDAQ:GLYC), Pfizer Inc. (NYSE ... - Equities Focus (registration)
GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With ... - MarketWatch

13:27 25/09/2014 Should Pfizer Inc. Buy Actavis plc?
Should Pfizer Inc. Buy Actavis plc?
Motley Fool - Sep 25, 2014
Earlier this year, a media circus erupted over Pfizer's reported interest in AstraZeneca (NYSE: AZN ) . The deal would have exceeded $100 billion and created a company roughly the same size as Johnson & Johnson. AstraZeneca brass, however, felt the ...
Pfizer-Actavis Merger Still A Possibility - Bidness ETC
Pfizer Said to Approach Actavis to Gauge Interest in Deal - Bloomberg

14:41 11/09/2014 Why I'd Avoid Pfizer Inc. Stock Despite the Dividend
Why I'd Avoid Pfizer Inc. Stock Despite the Dividend
Motley Fool - Sep 11, 2014
Pfizer's problem in the clinic is uncertainty regarding its ability to generate new blockbuster drugs. The company decided, along with almost every other Big Pharma simultaneously, to go after novel oncology and high cholesterol drugs to replace former ...

18:26 02/09/2014 Is It Time to Buy Pfizer Inc.'s Stock?
Is It Time to Buy Pfizer Inc.'s Stock?
Motley Fool - Sep 2, 2014
Since the recession ended, shareholders in Pfizer (NYSE: PFE ) , the world's largest pharmaceutical company by revenue, have seen their shares more than double.